SEC Filing Timeline
10-QAug 06, 2026
Quarterly report
8-KAug 06, 2026
Earnings release · Items 2.02,9.01
8-KJun 15, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KJun 10, 2026
Shareholder vote results · Items 5.07
10-QMay 11, 2026
Quarterly report
8-KMay 11, 2026
Earnings release · Items 2.02,9.01
8-KApr 30, 2026
Material agreement · Items 1.01,2.02,9.01
DEFA14AApr 30, 2026
Additional proxy
DEF 14AApr 30, 2026
Proxy statement
424B5Apr 29, 2026
Prospectus / offering
424B5Apr 27, 2026
Prospectus / offering
8-KApr 27, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KApr 10, 2026
Charter/bylaws amendment · Items 5.03,9.01
424B5Mar 02, 2026
Prospectus / offering
8-KMar 02, 2026
Material agreement · Items 1.01,7.01,8.01,9.01
Recent News (Finnhub)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24
Will Intellia’s (NTLA) Narrowing Losses and Heavy R&D Spend Shift Its Risk Reward Narrative?
Intellia Therapeutics Q2 Earnings Call Highlights
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ...
Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript